+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Passive Immunizing Drugs against Rabies Market - Global Forecast 2025-2030- Product Image
Passive Immunizing Drugs against Rabies Market - Global Forecast 2025-2030- Product Image
Sale

Passive Immunizing Drugs against Rabies Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 197 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6134348
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Senior decision-makers in pharmaceutical and biotechnology sectors are navigating an evolving landscape for passive immunizing agents against rabies, where advancements in biotechnology, shifting regulatory frameworks, and global supply chain adjustments shape market opportunities and vulnerabilities alike. The current environment demands not only technical innovation but also strategic insight to address growing prophylactic needs and optimize business outcomes.

Market Snapshot: Passive Immunizing Agents Against Rabies

The global market for passive immunizing agents against rabies is experiencing measurable growth, propelled by sustained demand in high-incidence regions, a broadening array of antibody-based therapeutics, and persistent investment in scalable biotechnological platforms. Market size and expansion rates are underpinned by rising awareness among healthcare providers, increasing collaboration between public health authorities and industry, and regulatory reforms that streamline product approvals. Organizations positioned to respond rapidly to both emergency response scenarios and routine prophylactic use will secure distinctive market advantages over the forecast period.

Scope & Segmentation

A comprehensive segmentation approach is adopted to ensure actionable market intelligence:

  • Product Types: Differentiated by formulation—liquid forms for rapid administration and lyophilized forms for longer shelf life and distribution agility.
  • Application Areas: Encompassing both postexposure and preexposure prophylaxis to address urgent and preventive needs.
  • Distribution Channels: Hospital, retail, and online pharmacies serving as critical touchpoints for product access across varying healthcare settings.
  • End Users: Clinics, hospitals, and research institutes employing immunizing agents for practical, comprehensive, and investigational uses.
  • Route of Administration: Includes intramuscular injection, intravenous injection, and wound infiltration to suit diverse clinical protocols.
  • Geographic Regions: Americas (with detailed U.S. state-level emphasis), Europe, Middle East & Africa, and Asia-Pacific capturing relevant local market forces, infrastructure, and uptake drivers.
  • Key Companies: Strategic activities of leading firms such as Grifols S.A., Takeda Pharmaceutical Company Limited, CSL Limited, Octapharma AG, Kedrion S.p.A., Serum Institute of India, and others are covered for benchmarking and partnership assessment.

Key Takeaways

  • Biotechnology innovations, such as monoclonal and polyclonal antibody platforms, are safeguarding production predictability and product safety profiles, giving organizations unique advantages as they scale.
  • Strategic alliances between academic, private, and contract manufacturing partners accelerate clinical innovation and widen access to passive immunizing agents in both routine and outbreak scenarios.
  • Market segmentation reflects marked variance by product presentation, distribution touchpoint, end user type, and administration method—each requiring tailored go-to-market strategies and training protocols.
  • Regional contrasts remain significant, with regulatory harmonization in some markets expediting approvals, while partnerships and government programs drive adoption in other geographies.
  • Competitive positioning is evolving, as ecosystem players integrate artificial intelligence, digital quality control, or advanced formulation technologies to strengthen pipeline differentiation and achieve greater resilience.

Tariff Impact: U.S. Tariff Revisions Reshape Supply Chain Dynamics

The introduction of new United States tariff schedules in 2025 has recalibrated cost structures in the supply chain for passive immunizing agents against rabies. Expanded import duties on raw materials and reagents have prompted manufacturers to adjust sourcing strategies, such as shifting to bulk procurement contracts or diversifying regional supplier bases. There is an emerging trend toward vertical integration and localized production to cushion against future external shocks. Organizations are adapting their inventory management and pricing policies to maintain supply continuity in priority regions.

Methodology & Data Sources

This report is built on a multi-phase data collection approach combining structured interviews with global industry leaders, regulatory experts, and clinical practitioners. Secondary research incorporated peer-reviewed scientific literature, patent data, and policy guidelines. Analytical rigor was enhanced through triangulation and iterative expert reviews to ensure strategic and operational insights are both credible and actionable.

Why This Report Matters: Outcome-Driven Strategic Benefits

  • Enables forward-looking portfolio management and roadmap planning for organizations targeting growth or defending competitive position in passive immunization against rabies.
  • Empowers stakeholders to tailor commercialization, distribution, and partnership strategies by providing clarity on technological, regulatory, and regional market shifts.
  • Mitigates risk by highlighting supply chain sensitivities to tariffs and by offering actionable recommendations for operational flexibility and resilience.

Conclusion: Navigating a Dynamic Market for Passive Immunizing Agents

With continuous innovation and changing regulatory requirements, aligning operational and strategic priorities is essential. This report supplies the clarity needed for senior decision-makers to drive successful outcomes and sustain access to vital rabies immunotherapies amid ongoing market transformation.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rapid adoption of monoclonal antibody therapies to replace traditional rabies immunoglobulins
5.2. Emergence of extended half-life antibody engineering enhancing post-exposure prophylaxis efficacy
5.3. Implementation of intradermal administration protocols to optimize limited rabies immunoglobulin supplies
5.4. Strategic partnerships between local manufacturers and global biotech firms improving RIG production capacity
5.5. Regulatory approvals of novel fully human rabies mAbs driving market diversification in Asia Pacific
5.6. Cost reduction initiatives through recombinant antibody platforms reducing manufacturing expenses
5.7. Deployment of mobile serum fractionation units to strengthen rabies immunoglobulin availability in remote areas
5.8. Innovations in lyophilized RIG formulations to enhance cold chain independence in tropical regions
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Passive Immunizing Drugs against Rabies Market, by Product Type
8.1. Introduction
8.2. Formulation
8.2.1. Liquid Form
8.2.2. Lyophilized Form
9. Passive Immunizing Drugs against Rabies Market, by Application
9.1. Introduction
9.2. Postexposure Prophylaxis
9.3. Preexposure Prophylaxis
10. Passive Immunizing Drugs against Rabies Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy
11. Passive Immunizing Drugs against Rabies Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Hospitals
11.4. Research Institutes
12. Passive Immunizing Drugs against Rabies Market, by Route Of Administration
12.1. Introduction
12.2. Intramuscular Injection
12.3. Intravenous Injection
12.4. Wound Infiltration
13. Americas Passive Immunizing Drugs against Rabies Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Passive Immunizing Drugs against Rabies Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Passive Immunizing Drugs against Rabies Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Grifols S.A.
16.3.2. Takeda Pharmaceutical Company Limited
16.3.3. CSL Limited
16.3.4. Octapharma AG
16.3.5. Kedrion S.p.A.
16.3.6. Serum Institute of India Private Limited
16.3.7. Les Laboratoires Français du Fractionnement et des Biotechnologies (LFB)
16.3.8. Shandong Taibang Biopharmaceutical Co., Ltd.
16.3.9. Tianjin Kinghem Pharmaceutical Co., Ltd.
16.3.10. Haffkine Bio-Pharmaceutical Corporation Limited
17. ResearchAI18. ResearchStatistics19. ResearchContacts20. ResearchArticles21. Appendix
List of Figures
FIGURE 1. PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET: RESEARCHAI
FIGURE 26. PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET: RESEARCHSTATISTICS
FIGURE 27. PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET: RESEARCHCONTACTS
FIGURE 28. PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY LIQUID FORM, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY LIQUID FORM, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY LYOPHILIZED FORM, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY LYOPHILIZED FORM, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY POSTEXPOSURE PROPHYLAXIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY POSTEXPOSURE PROPHYLAXIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PREEXPOSURE PROPHYLAXIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PREEXPOSURE PROPHYLAXIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY INTRAVENOUS INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY INTRAVENOUS INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY WOUND INFILTRATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY WOUND INFILTRATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. AMERICAS PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 50. AMERICAS PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 51. AMERICAS PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 52. AMERICAS PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 53. AMERICAS PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 54. AMERICAS PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 55. AMERICAS PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 56. AMERICAS PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 57. AMERICAS PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 58. AMERICAS PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 59. AMERICAS PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 60. AMERICAS PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 61. AMERICAS PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 62. AMERICAS PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 63. UNITED STATES PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 64. UNITED STATES PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 65. UNITED STATES PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 66. UNITED STATES PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 67. UNITED STATES PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 68. UNITED STATES PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 69. UNITED STATES PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 70. UNITED STATES PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 71. UNITED STATES PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 72. UNITED STATES PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 73. UNITED STATES PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 74. UNITED STATES PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 75. UNITED STATES PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 76. UNITED STATES PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 77. CANADA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 78. CANADA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 79. CANADA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 80. CANADA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 81. CANADA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 82. CANADA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 83. CANADA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 84. CANADA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 85. CANADA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 86. CANADA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 87. CANADA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 88. CANADA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 89. MEXICO PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 90. MEXICO PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 91. MEXICO PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 92. MEXICO PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 93. MEXICO PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 94. MEXICO PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 95. MEXICO PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 96. MEXICO PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 97. MEXICO PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 98. MEXICO PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 99. MEXICO PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 100. MEXICO PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 101. BRAZIL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 102. BRAZIL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 103. BRAZIL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 104. BRAZIL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 105. BRAZIL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 106. BRAZIL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 107. BRAZIL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 108. BRAZIL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 109. BRAZIL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 110. BRAZIL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 111. BRAZIL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 112. BRAZIL PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 113. ARGENTINA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 114. ARGENTINA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 115. ARGENTINA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 116. ARGENTINA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 117. ARGENTINA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 118. ARGENTINA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 119. ARGENTINA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 120. ARGENTINA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 121. ARGENTINA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 122. ARGENTINA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 123. ARGENTINA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 124. ARGENTINA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 139. UNITED KINGDOM PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 140. UNITED KINGDOM PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 141. UNITED KINGDOM PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 142. UNITED KINGDOM PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 144. UNITED KINGDOM PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 146. UNITED KINGDOM PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 148. UNITED KINGDOM PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 149. UNITED KINGDOM PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 150. UNITED KINGDOM PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 151. GERMANY PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 152. GERMANY PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 153. GERMANY PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 154. GERMANY PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 155. GERMANY PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 156. GERMANY PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 157. GERMANY PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 158. GERMANY PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 159. GERMANY PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 160. GERMANY PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 161. GERMANY PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 162. GERMANY PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 163. FRANCE PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 164. FRANCE PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 165. FRANCE PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 166. FRANCE PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 167. FRANCE PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 168. FRANCE PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 169. FRANCE PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 170. FRANCE PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 171. FRANCE PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 172. FRANCE PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 173. FRANCE PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 174. FRANCE PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 175. RUSSIA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 176. RUSSIA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 177. RUSSIA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 178. RUSSIA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 179. RUSSIA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 180. RUSSIA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 181. RUSSIA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 182. RUSSIA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 183. RUSSIA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 184. RUSSIA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 185. RUSSIA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 186. RUSSIA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 187. ITALY PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 188. ITALY PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 189. ITALY PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 190. ITALY PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 191. ITALY PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 192. ITALY PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 193. ITALY PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 194. ITALY PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 195. ITALY PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 196. ITALY PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 197. ITALY PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 198. ITALY PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 199. SPAIN PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 200. SPAIN PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 201. SPAIN PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 202. SPAIN PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 203. SPAIN PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 204. SPAIN PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 205. SPAIN PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 206. SPAIN PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 207. SPAIN PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 208. SPAIN PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 209. SPAIN PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 210. SPAIN PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 211. UNITED ARAB EMIRATES PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 212. UNITED ARAB EMIRATES PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 213. UNITED ARAB EMIRATES PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 214. UNITED ARAB EMIRATES PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 215. UNITED ARAB EMIRATES PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 216. UNITED ARAB EMIRATES PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 217. UNITED ARAB EMIRATES PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 218. UNITED ARAB EMIRATES PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 219. UNITED ARAB EMIRATES PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 220. UNITED ARAB EMIRATES PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 221. UNITED ARAB EMIRATES PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 222. UNITED ARAB EMIRATES PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 223. SAUDI ARABIA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 224. SAUDI ARABIA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 225. SAUDI ARABIA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 226. SAUDI ARABIA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 227. SAUDI ARABIA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 228. SAUDI ARABIA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 229. SAUDI ARABIA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 230. SAUDI ARABIA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 231. SAUDI ARABIA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 232. SAUDI ARABIA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 233. SAUDI ARABIA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 234. SAUDI ARABIA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 235. SOUTH AFRICA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 236. SOUTH AFRICA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 237. SOUTH AFRICA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 238. SOUTH AFRICA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 239. SOUTH AFRICA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 240. SOUTH AFRICA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 241. SOUTH AFRICA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 242. SOUTH AFRICA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 244. SOUTH AFRICA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 246. SOUTH AFRICA PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 247. DENMARK PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 248. DENMARK PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 249. DENMARK PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 250. DENMARK PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 251. DENMARK PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 252. DENMARK PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 253. DENMARK PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 254. DENMARK PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 255. DENMARK PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 256. DENMARK PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 257. DENMARK PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 258. DENMARK PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 259. NETHERLANDS PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 260. NETHERLANDS PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 261. NETHERLANDS PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 262. NETHERLANDS PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 263. NETHERLANDS PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 264. NETHERLANDS PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 265. NETHERLANDS PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 266. NETHERLANDS PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 267. NETHERLANDS PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 268. NETHERLANDS PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 269. NETHERLANDS PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 270. NETHERLANDS PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 271. QATAR PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 272. QATAR PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 273. QATAR PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
TABLE 274. QATAR PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
TABLE 275. QATAR PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 276. QATAR PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 277. QATAR PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 278. QATAR PASSIVE IMMUNIZING DRUGS AGAINST RABIES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 279. QATAR PASSIVE IMMUNIZING DRUGS AGAI

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Passive Immunizing Drugs against Rabies Market report include:
  • Grifols S.A.
  • Takeda Pharmaceutical Company Limited
  • CSL Limited
  • Octapharma AG
  • Kedrion S.p.A.
  • Serum Institute of India Private Limited
  • Les Laboratoires Français du Fractionnement et des Biotechnologies (LFB)
  • Shandong Taibang Biopharmaceutical Co., Ltd.
  • Tianjin Kinghem Pharmaceutical Co., Ltd.
  • Haffkine Bio-Pharmaceutical Corporation Limited

Related Topics

Related Reports

Anti-Rabies Serum Market Report 2025 - Product Image

Anti-Rabies Serum Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Anthrax Treatment - Global Strategic Business Report - Product Image

Anthrax Treatment - Global Strategic Business Report

  • Report
  • 373 Pages
  • Global
From
Rabies Treatment - Global Strategic Business Report - Product Image

Rabies Treatment - Global Strategic Business Report

  • Report
  • 179 Pages
  • Global
From
Rabies Infection Pipeline Analysis Report 2025 - Product Image

Rabies Infection Pipeline Analysis Report 2025

  • Report
  • 200 Pages
  • Global
From
Imovax Rabies Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts - Product Image

Imovax Rabies Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

  • Report
  • 175 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.